Inhibikase Therapeutics (IKT) EPS (Weighted Average and Diluted) (2021 - 2024)
Historic EPS (Weighted Average and Diluted) for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2024 value amounting to -$0.55.
- Inhibikase Therapeutics' EPS (Weighted Average and Diluted) rose 2536.09% to -$0.55 in Q4 2024 from the same period last year, while for Sep 2025 it was -$0.14, marking a year-over-year increase of 9364.39%. This contributed to the annual value of -$1.21 for FY2024, which is 6382.23% up from last year.
- Per Inhibikase Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.55 for Q4 2024, which was up 2536.09% from -$0.66 recorded in Q3 2024.
- Inhibikase Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.18 for Q3 2021, and its period low was -$1.11 during Q2 2023.
- Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$0.73 (2023), whereas its average is -$0.67.
- In the last 5 years, Inhibikase Therapeutics' EPS (Weighted Average and Diluted) crashed by 48888.89% in 2022 and then surged by 3962.01% in 2024.
- Inhibikase Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.28 in 2021, then tumbled by 270.75% to -$1.03 in 2022, then increased by 28.84% to -$0.73 in 2023, then grew by 25.36% to -$0.55 in 2024.
- Its EPS (Weighted Average and Diluted) was -$0.55 in Q4 2024, compared to -$0.66 in Q3 2024 and -$0.67 in Q2 2024.